{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:41:54Z","timestamp":1765827714195,"version":"3.48.0"},"reference-count":23,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,10,21]]},"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore patient, caregiver and physician perceptions and attitudes regarding the balance of benefit and risk in using antibacterial drugs developed through streamlined development processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Semistructured focus groups and in-depth interviews were conducted to elicit perceptions and attitudes about the use of antibacterial drugs to treat multidrug-resistant infections. Participants were given background information about antibiotic resistance, streamlined drug development programmes and FDA drug approval processes. Audio recordings of focus groups\/interviews were reviewed and quotes excerpted and categorised to identify key themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Two primary stakeholder groups were engaged: one comprising caregivers, healthy persons and patients who had recovered from or were at risk of resistant infection (N=67; 11 focus groups); and one comprising physicians who treat resistant infections (N=23).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Responses from focus groups\/interviews indicated widespread awareness among patients\/caregivers and physicians of the seriousness of the problem of antibacterial resistance. Both groups were willing to accept a degree of uncertainty regarding the balance of risk and benefit in a new therapy where a serious unmet need exists, but also expressed a desire for rigorous monitoring and rapid, transparent reporting of safety\/effectiveness data. Both groups wanted to ensure that &gt;1 physician had input on whether to treat patients with antibiotics developed through a streamlined process. Some patients\/caregivers unfamiliar with exigencies of critical care suggested a relatively large multidisciplinary team, while physicians believed individual expert consultations would be preferable. Both groups agreed that careful oversight and stewardship of antibacterial drugs are needed to ensure patient safety, preserve efficacy and prevent abuse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Groups comprising patients\/caregivers and physicians were aware of serious issues posed by resistant infections and the lack of effective antibacterial drug therapies and shared a consensus that streamlined development programmes represent a necessary response to the resistance crisis, but one that requires enhanced safeguards and risk communication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013561","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T05:55:43Z","timestamp":1479102943000},"page":"e013561","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Patient and physician attitudes regarding risk and benefit in streamlined development programmes for antibacterial drugs: a qualitative analysis"],"prefix":"10.1136","volume":"6","author":[{"given":"Thomas L","family":"Holland","sequence":"first","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA"},{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Mikita","sequence":"additional","affiliation":[{"name":"Patient Advocates in Research (PAIR), Danville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Bloom","sequence":"additional","affiliation":[{"name":"InFocus Research, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Roberts","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"McCall","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Collyar","sequence":"additional","affiliation":[{"name":"Patient Advocates in Research (PAIR), Danville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Santiago","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Tiernan","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Toerner","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"2025121511314666000_6.11.e013561.1","unstructured":"World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. http:\/\/apps.who.int\/iris\/bitstream\/10665\/112647\/1\/WHO_HSE_PED_AIP_2014.2_eng.pdf?ua=1 (accessed 12 Nov 2015)."},{"key":"2025121511314666000_6.11.e013561.2","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/ (accessed 12 Nov 2015)."},{"key":"2025121511314666000_6.11.e013561.3","doi-asserted-by":"publisher","DOI":"10.1086\/420937"},{"key":"2025121511314666000_6.11.e013561.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)01283-1"},{"key":"2025121511314666000_6.11.e013561.5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl373"},{"key":"2025121511314666000_6.11.e013561.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2007.08.007"},{"key":"2025121511314666000_6.11.e013561.7","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"2025121511314666000_6.11.e013561.8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.116"},{"key":"2025121511314666000_6.11.e013561.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00638-15"},{"key":"2025121511314666000_6.11.e013561.10","first-page":"157","article-title":"Challenges in developing new antibacterial drugs","volume":"10","author":"Williams","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"2025121511314666000_6.11.e013561.11","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00030-10"},{"key":"2025121511314666000_6.11.e013561.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06300.x"},{"key":"2025121511314666000_6.11.e013561.13","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.131"},{"key":"2025121511314666000_6.11.e013561.14","unstructured":"US Food and Drug Administration. Draft guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. July 2013. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm359184.pdf (accessed 12 Nov 2015)."},{"key":"2025121511314666000_6.11.e013561.15","unstructured":"Clinical Trials Transformation Initiative. Who we are. http:\/\/www.ctti-clinicaltrials.org\/who-we-are (accessed 12 Nov 2015)."},{"key":"2025121511314666000_6.11.e013561.16","doi-asserted-by":"crossref","unstructured":"Corbin J , Strauss A . Basics of qualitative research: techniques and procedures for developing grounded theory. 3rd edn. Thousand Oaks, CA: Sage Publications, 2008.","DOI":"10.4135\/9781452230153"},{"key":"2025121511314666000_6.11.e013561.17","unstructured":"Patton MQ . Qualitative research and evaluation methods. London: Sage Publications, 2002."},{"key":"2025121511314666000_6.11.e013561.18","unstructured":"Goldman AE , McDonald SS . The group depth interview: principles and practice. Englewood Cliffs, NJ: Prentice-Hall, 1987:7\u201323."},{"key":"2025121511314666000_6.11.e013561.19","unstructured":"McCracken G . The Long Interview. Newbury Park, CA: Sage Publications, 2008."},{"key":"2025121511314666000_6.11.e013561.20","unstructured":"Green J , Thorogood N . Qualitative methods for health research. 2nd edn. Thousand Oaks, CA: Sage Publications, 2009."},{"key":"2025121511314666000_6.11.e013561.21","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X05279903"},{"key":"2025121511314666000_6.11.e013561.22","unstructured":"Code of Federal Regulations. 21 CFR 312.80. Subpart E. Drugs intended to treat life-threatening and severely-debilitating illnesses\u2014purpose. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.5 (accessed 11 Apr 2016)."},{"key":"2025121511314666000_6.11.e013561.23","unstructured":"World Health Organization. Antibiotic resistance: multi-country public awareness survey. Executive summary. http:\/\/apps.who.int\/iris\/bitstream\/10665\/194460\/1\/9789241509817_eng.pdf?ua=1\/ (accessed 8 Jan 2015)."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:31:53Z","timestamp":1765827113000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,10]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1136\/bmjopen-2016-013561"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013561","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}